Meldonium as the application and medicine for preventing or treating acute brain injury at high altitude
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology for acute brain injury and meldonium, applied in the field of biomedicine, can solve the problem of single category
Active Publication Date: 2021-06-11
ACADEMY OF MILITARY MEDICAL SCI
View PDF0 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0005] Currently, acetazolamide is the drug that has been marketed internationally to prevent altitude sickness, and Rhodiola is a drug that has been marketed in China, and the category is relatively single.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0108] Meldonium was administered at a dose of 50 mg / kg.
[0109] The solid oral medicament of the present invention is composed of the following materials: 200 parts of meldonium, 10 parts of diluent, 10 parts of lubricant, 10 parts of binder, 10 parts of disintegrant, 10 parts of boiling mixture, 10 parts of sweetener, 2 parts of dye, 10 parts of wetting agent, 5000 parts of distilled water;
[0110] The above-mentioned solid oral medicine was administered continuously for three days, and the dosage was 8 mL / kg.
Embodiment 2
[0112] Meldonium was administered at a dose of 100 mg / kg.
[0113] The solid oral medicament of the present invention is composed of the following materials: 200 parts of meldonium, 10 parts of diluent, 10 parts of lubricant, 10 parts of binder, 10 parts of disintegrant, 10 parts of boiling mixture, 10 parts of sweetener, 2 parts of dye, 10 parts of wetting agent, 5000 parts of distilled water;
[0114] The above-mentioned solid oral medicine was administered continuously for three days, and the dosage was 8 mL / kg.
Embodiment 3
[0116] Meldonium was administered at a dose of 100 mg / kg.
[0117] The solid oral medicament of the present invention is composed of the following materials: 200 parts of meldonium, 10 parts of diluent, 10 parts of lubricant, 10 parts of binder, 10 parts of disintegrant, 10 parts of boiling mixture, 10 parts of sweetener, 2 parts of dye, 10 parts of wetting agent, 5000 parts of distilled water;
[0118] The above-mentioned solid oral medicine was administered continuously for three days, and the dosage was 8 mL / kg.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The meldonium of the present invention is used as the prevention or treatment of plateau acute brain injury, and the meldonium is applied to the prevention or treatment of plateau acute brain injury. According to the research of the present invention, it is found that meldonium can effectively reduce or improve the brain injury caused by high altitude hypoxic environment. Therefore, the present invention relates to the use of meldonium for preventing acute brain injury at high altitude. The test shows that Meldonium has a significant protective effect on the damage of brain nerve cells caused by hypobaric hypoxia, and the effect is equivalent to that of the positive control drug acetazolamide. Meldonium can significantly reduce pathological damages such as nerve cell shrinkage, nuclear pyknosis and nuclear fragmentation caused by plateau hypoxia, and can effectively improve brain blood supply deficiency caused by plateau hypoxia; in addition, meldonium can significantly improve Mitochondrial dysfunction in the hippocampus induced by plateau hypoxia reduces oxidative stress damage in brain tissue.
Description
technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to the medicinal use of meldonium for preventing or treating acute brain injury at high altitude. Background technique [0002] Altitude sickness, also known as altitude sickness (mountain sickness), is an idiosyncratic and common disease in plateau areas above 3000m above sea level. The collective name of the clinical syndromes is the special state of organs, tissues, cells, etc. to adapt to the hypoxic environment. [0003] The acute high-altitude brain damage involved in the present invention includes, but is not limited to, high-altitude headache, high-altitude coma, high-altitude cerebral edema, and diseases in which brain abnormalities exist simultaneously or alone. [0004] The clinical manifestations of high-altitude brain damage described in the present invention are selected from headache, dizziness, rapid heart rate, chest tightness, shortness of breath, deep breat...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more